Background. Dengue virus (DENV) can cause life-threatening disease characterized by endothelial dysfunction and vascular leakage. DENV nonstructural protein 1 (NS1) induces human endothelial hyperpermeability and vascular leak in mice, and NS1 vaccination confers antibody-mediated protective immunity. We evaluated the magnitude, cross-reactivity, and functionality of NS1-specific IgG antibody responses in sera from a phase 2 clinical trial of Takeda's live-attenuated tetravalent dengue vaccine candidate (TAK-003).
Dengue is the most prevalent human arboviral disease worldwide, with approximately 390 million annual infections and half the world's population at risk of infection from 1 of 4 dengue virus serotypes (DENV-1-4) [1] . DENV is a flavivirus transmitted by Aedes aegypti or Aedes albopictus mosquitoes. Outcomes range from asymptomatic infection to dengue fever (DF) to severe dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS) [2] . Several DENV vaccine candidates are under development. A chimeric yellow fever virus-tetravalent dengue vaccine (Dengvaxia, Sanofi Pasteur) is approved for age ≥9 years in 20 countries [3] [4] [5] . However, Dengvaxia has been associated with increased risk of severe disease in younger and seronegative individuals [4, 6, 7] . Therefore, an urgent need exists for a dengue vaccine that can protect all age groups against all 4 DENV serotypes, irrespective of DENV serostatus. In addition to neutralizing antibodies (NAb) against the viral envelope (E) protein, there is increasing evidence for protective roles of cell-mediated and humoral responses against DENV nonstructural proteins, especially nonstructural protein 1 (NS1) [8] .
NS1 is the only viral protein secreted from DENV-infected cells and plays several roles in viral replication and immune evasion [9] . NS1 can act as a viral toxin and contributes to pathogenesis through an endothelial cell-intrinsic route, where the endothelial glycocalyx is degraded by sialidases and the cathepsin L/heparanase pathway [10, 11] , and a cytokine-dependent route where NS1 stimulates inflammatory cytokine production from immune cells [12] . DENV infection elicits NS1-specific antibodies, with antibody found in primary infection convalescent sera and in acute and convalescent phases during secondary infection [13] [14] [15] [16] [17] . No differences in anti-NS1 antibody titers have been observed between DF and DHF/DSS patients [13] [14] [15] [16] [17] ; however, antibodies to specific NS1 epitopes are higher in patients with more severe dengue [18] . Furthermore, vaccination with NS1 protects mice from lethal vascular leak, and passive transfer of NS1-specific serum abrogates NS1-induced lethality in vivo [19] . The role of DENV NS1-specific immunity in protection mediated by vaccination in humans has not been investigated.
Takeda's tetravalent dengue vaccine (TAK-003) consists of an attenuated DENV-2 virus backbone (TDV-2) and 3 chimeric viruses containing the premembrane/membrane and E protein genes of DENV-1, -3, and -4 genetically engineered into TDV-2 [20] . TAK-003 induced NAb responses and seroconversion to all 4 DENV serotypes in phase 1 and 2 studies and was generally safe and well tolerated in children and adults from dengue-endemic and nonendemic countries [21] [22] [23] [24] . Here, we determined the magnitude and functionality of NS1-specific IgG responses elicited by TAK-003. Vaccination stimulated strong, sustained, and serotype cross-reactive TDV-2 NS1-specific IgG responses in DENV-naive TAK-003 recipients. Additionally, the DENV-2 NS1 IgG response protected against DENV-2 NS1-induced endothelial hyperpermeability and endothelial glycocalyx-like layer (EGL) degradation in vitro. Cross-reactive IgG also protected against DENV-1, -3, and -4 NS1-induced barrier dysfunction and correlated with the respective IgG concentrations. These results demonstrate that TAK-003 elicits both NAbs to viral structural proteins [25] and NS1-specific humoral responses [25] and that NS1-specific IgG responses can protect against NS1-mediated toxicity in vitro.
METHODS

Ethics Statement
Study DEN-203 (ClinicalTrials.gov identifier: NCT01511250) was conducted in accordance with Institutional Review Board regulations in the US Code of Federal Regulations and all applicable local regulations. Participants gave written informed consent; children provided verbal or written assent and had written informed consent given by a parent or legal guardian, according to local regulations.
Cell Culture
Human pulmonary microvascular endothelial cell line HPMEC-ST1.6r (HPMEC) was kindly donated by Dr J.C. Kirkpatrick (Johannes Gutenberg University, Germany) and grown as previously described [11] .
Recombinant NS1 Proteins
For transendothelial electrical resistance (TEER) assays and confocal microscopy, recombinant NS1 from DENV-1 (Nauru/ Western Pacific/1974), DENV-2 (Thailand/16681/84), DENV-3 (Sri Lanka D3/H/IMTSSA-SRI/2000/1266), and DENV-4 (Dominica/814669/1981), greater than 95% purity and certified to be free of endotoxin contaminants, was produced in HEK293 cells by the Native Antigen Company. NS1 preparations were confirmed to be free of bacterial endotoxins using the Endpoint Chromogenic Limulus Amebocyte Lysate QCL-1000TM kit (Lonza) [11] .
For enzyme-linked immunosorbent assays (ELISA), recombinant DENV-2 (Thailand/16681/84) NS1 from Abcam; and DENV-1 (Nauru/Western Pacific/1974), DENV-3 (Sri Lanka D3/H/IMTSSA-SRI/2000/1266), and DENV-4 (Dominica/814669/1981) NS1 from the Native Antigen Company were used. Purity and integrity of NS1 was verified by sodium dodecyl sulfate polyacrylamide gel electrophoresis, and concentrations were determined using the bicinchoninic acid assay.
Serum Samples
Individual sera from the phase 2 DEN-203 clinical trial were used throughout this study. DEN-203 enrolled 360 participants to assess safety and immunogenicity of TAK-003 in healthy adults and children living in dengue-endemic countries and was conducted in 2 parts: Part 1-age descending (21-45, 12-20, 6-11, and 1.5-5 years); and Part 2-expansion, ages 1.5 to 11 years. Participants were randomized to receive either 0.5 mL subcutaneous injection of TAK-003 or placebo [24] . Serum samples were collected prevaccination (day 0) and at days 7, 14, 28, 90, 120, 180, 360, and 1080 postvaccination. NAb titers from microneutralization tests (MNT) performed on day 0 samples were used to classify the samples into DENV-naive or preimmune categories [23] .
Control DENV-positive sera (Discovery Life Sciences) were tested for NS1-specific IgG levels and pooled to generate the reference standard/positive control (DLS pool). Negative control serum (Bioreclamation IVT) from DENV-negative individuals from nonendemic countries was pooled and tested for DENV reactivity and was negative by reverse transcription polymerase chain reaction, MNT, and binding ELISA.
Monoclonal Antibodies
Wheat germ agglutinin conjugated to Alexa Fluor 647 (WGA-A647, Molecular Probes) and Ab Heparan Sulfate, purified (clone F58-10E4, Amsbio) were used for staining sialic acid and heparan sulfate, respectively. The secondary detection antibody in confocal microscopy experiments was donkey anti-mouse IgM conjugated to Alexa Fluor 488 (Jackson).
Anti-NS1 IgG Enzyme-linked Immunosorbent Assay
Maxisorp 96-well flat bottom microtiter plates (NUNC) were coated with DENV NS1 (1.0 μg/mL) in carbonate/bicarbonate buffer pH 9.6 overnight at 4°C. Plates were washed with 0.01 M phosphate-buffered saline + 0.1% Tween 20 (PBS-T) and blocked with SuperBlock T20 Blocking Buffer (ThermoFisher Scientific) for 1 hour at 37°C. Plates were washed with PBS-T, then 4-fold serially diluted serum samples and controls were added and incubated for 60 minutes at 37°C. Plates were washed with PBS-T and incubated with peroxidase-conjugated goat anti-human IgG-gamma chain (Fitzgerald Inc.) in PBS-T for 60 minutes at 37°C. Plates were washed with PBS-T and color was developed with ABTS Peroxidase Substrate (SeraCare) for 15 minutes at room temperature, stopped with 1× ABTS Peroxidase Stop Solution (KPL), and optical density at 405 nm measured using a Spectramax 384 Plus/306200 plate reader (Molecular Devices) in conjunction with SoftMax Pro software version 7.0.3 (Molecular Devices). The concentration of anti-DENV NS1 IgG in serum samples was determined relative to the reference standard and is reported in relative ELISA units per milliliter (RU/mL).
TEER Assay
NS1-induced endothelial hyperpermeability was evaluated by measuring TEER of HPMEC grown on 24-well Transwell polycarbonate membranes (Transwell permeable support, 0.4 μM, 6.5 mm insert; Corning Inc.) as previously described [11, 19] . Briefly, TEER was measured in Ohms (Ω) every 3 hours following addition of NS1 and serum using an Epithelial Volt Ohm Meter with "chopstick" electrodes (World Precision Instruments). Thirty μL of culture supernatant was removed from the apical chamber and replaced with 30 μL of serum samples immediately preceding addition of DENV NS1 proteins. Untreated cells grown on Transwells were used as negative controls, and Transwells with medium alone were used for blank resistance measurements. Relative TEER represents a ratio of resistance values (Ω) as follows: (Ω experimental condition − Ω medium alone)/ (Ω nontreated endothelial cells − Ω medium alone). Twenty-four hours posttreatment, 50% of upper and lower chamber media was replaced by fresh medium.
Fluorescence Microscopy
Microscopy was performed as previously described [11] . For imaging experiments, HPMEC were grown on coverslips coated with 0.2% gelatin (Sigma). The distribution of sialic acid and heparan sulfate was examined on confluent HPMEC monolayers treated with DENV-2 NS1 (5 µg/mL) and TAK-003 serum or negative or positive control serum (30 µL each) and fixed with 4% paraformaldehyde at 6 hours posttreatment. Primary antibodies were incubated overnight at 4°C, and detection was performed using secondary antibodies conjugated to Alexa fluorophores (488 and 647) using a Zeiss LSM 710 Axio Observer inverted fluorescence microscope equipped with a 34-channel spectral detector. Images acquired using Zen 2010 software (Zeiss) were processed and analyzed with ImageJ [26] . All RGB images were converted to grayscale, then mean grayscale values and integrated density from selected areas were taken, along with adjacent background readings, and plotted as mean fluorescence intensity.
Statistical Analysis
Statistical analyses were performed and all graphs generated using GraphPad Prism 7.0 software. For NS1 IgG concentrations, 1-way ANOVA with Tukey or Sidak multiple comparison test was used. For correlation analyses, the net area under the curve (AUC) was taken from all curves in all TEER experiments using a baseline of Y = 1 while also considering peaks that went below the baseline. For each experiment, the AUC of NS1 + serum was subtracted from the AUC of NS1 alone, providing a reduction in relative TEER for each serum sample, which was then plotted against the log 10 IgG concentration, and correlation analysis was performed. The Pearson correlation coefficient and 2-tailed P values are reported within the figures.
RESULTS
TAK-003 Induces a Significant NS1-Specific IgG Response in DENV-Naive Vaccine Recipients
We used an indirect ELISA to measure pre-and postvaccination DENV-2 NS1-specific IgG response in DENV-naive and DENV-preimmune recipients of placebo or TAK-003. In DENV-naive recipients, TAK-003 elicited a significant increase in NS1-specific IgG at all time points postvaccination ( Figure  1 ), compared to no NS1-specific IgG detected in DENV-naive placebo recipients. No significant differences were observed in NS1-specific IgG levels in the DENV-preimmune group between placebo or TAK-003 recipients across the study time course (Figure 1 ). The anti-NS1 IgG concentration in DENVnaive vaccinees was significantly increased after the first dose (day 0 vs 28) and boosted after the second dose (day 28 and 90 vs 120), and antibodies were sustained through day 360 ( Figure 1 and Supplementary Table 1 ). In DENV-preimmune vaccinees, no significant differences were observed in NS1-specific IgG concentrations pre-and postvaccination through day 90. Anti-NS1 IgG levels increased after the second dose and remained above prevaccination level through day 360 ( Figure 1 and Supplementary Table 1 ). Next, we compared anti-NS1 IgG concentrations between DENV-naive or preimmune TAK-003 recipients at matched time points pre-and postvaccination (Supplementary Figure 1 and Supplementary  Table 2 ). After the first dose, NS1-specific IgG responses were higher in DENV-preimmune vaccinees than in DENV-naive vaccinees (Supplementary Figure 1) ; however, NS1-specific IgG levels were comparable after the second immunization (day 120 and 180) and then declined by day 360 postvaccination. After 2 vaccinations, NS1-specific IgG levels increased ≥4-fold in 38% of DENV-preimmune vaccine recipients compared to prevaccination levels. In contrast, NS1-specific IgG levels increased ≥4-fold in 100% of DENV-naive vaccine recipients after the second dose, compared to prevaccination levels (Supplementary Table 2 ). DENV infection elicits both serotype-specific and cross-reactive NS1-specific antibodies [13, 14, 27] , and cross-reactive NS1-specific antibodies can confer partial protection against lethal DENV-2 infection in mice [19] . The NS1 component of TAK-003 is encoded by the attenuated DENV-2 backbone, and vaccination elicits IgG against DENV-2 NS1. To evaluate whether the TAK-003-elicited anti-DENV-2 NS1 IgG response was cross-reactive against NS1 from other serotypes, sera from DENV-naive and DENV-preimmune vaccinees were tested for IgG against recombinant DENV-1, -3, and -4 NS1. Vaccination elicited a significant increase in IgG against NS1 from other serotypes in DENV-naive subjects, whereas levels of NS1-specific IgG to the other serotypes were not significantly increased in DENV-preimmune subjects (Figure 2 ). Following vaccination of naive subjects, seroconversion rates (defined as IgG concentration increase >1.7 log 10 ) to DENV-1, -3, and -4 were 100%, 85%, and 66%, respectively. Seroconversion rates in DENV-preimmune vaccinees against NS1 from all 4 DENV serotypes, pre-and postvaccination, were ≥88%.
NS1-Specific IgG Responses in TAK-003-Vaccinated Individuals Abrogate
DENV-2 NS1-Induced Endothelial Hyperpermeability In Vitro
NS1 from all 4 DENV serotypes can induce hyperpermeability of HPMEC as measured by reduction in TEER [11] , and this can be blocked using NS1-immune sera [19] . Sera from 12 subjects (6 DENV-naive, 6 DENV-preimmune) at day 0 prevaccination and day 120 postvaccination were evaluated by TEER to assess the effect of TAK-003-induced NS1-specific IgG responses on NS1-mediated endothelial hyperpermeability. DENV-naive prevaccination serum samples did not prevent NS1-mediated barrier dysfunction, but day 120 postvaccination samples from all naive vaccinees blocked decreases in TEER ( Figure 3A and Supplementary Figure 3) . Preimmune day 0 samples protected to varying degrees, while all day 120 postvaccination samples completely abrogated NS1-induced hyperpermeability ( Figure  3B and Supplementary Figure 4) . Pooled positive control serum also completely prevented DENV-2 NS1-induced hyperpermeability, while negative control serum did not (Supplementary Figure 2) . The reduction in NS1-mediated hyperpermeability mediated by TAK-003 sera, measured by AUC from each TEER analysis, strongly correlated with NS1-specific antibody levels (r = 0.8826; P < .0001) ( Figure 3C ). Taken together, these results indicate that immunization with TAK-003 stimulates a protective anti-DENV-2 NS1 antibody response capable of blocking NS1-mediated hyperpermeability in vitro.
TAK-003-Elicited Anti-NS1 IgG Responses Are Cross-Protective Against
Endothelial Hyperpermeability Induced by NS1 From Other DENV
Serotypes, and Protection Correlates With Cross-Reactive Antibody
Concentration
We evaluated whether the TAK-003-elicited, cross-reactive anti-DENV-2 NS1 IgG response was cross-protective against DENV-1, -3, and -4 NS1-induced endothelial hyperpermeability. We analyzed a subset of DENV-naive and preimmune day 0 and day 120 postvaccination samples against recombinant DENV-1, -3, and -4 NS1 using TEER and found that sera from TAK-003 recipients could cross-protect against NS1 from other DENV serotypes (Supplementary Figures 6, 7 , and 8). DENV-positive control serum fully blocked hyperpermeability induced by DENV-1-4 NS1 while negative control serum did not. As observed with the anti-DENV-2 NS1 IgG response, the ability to prevent DENV-1, -3, and -4 NS1-induced hyperpermeability correlated with the magnitude of cross-reactive NS1-specific antibodies in each sample (Figure 4 ). Sera from DENV-preimmune vaccinees reduced DENV-1, -3, and -4 NS1-mediated hyperpermeability, both pre-and postvaccination (Supplementary Figures 6, 7 , and 8). These results suggest that vaccination of naive recipients with TAK-003 elicits a protective, cross-reactive, NS1-specific IgG response capable of blocking NS1-mediated hyperpermeability.
The NS1-Specific IgG Response to TAK-003 is Comparable to DENV
Infection
Serial dilutions of pooled serum from DENV-infected individuals or DENV-naive vaccinees at day 120 postvaccination were evaluated by TEER and ELISA, and the reduction in relative TEER was correlated with NS1 IgG concentrations against each DENV serotype. There was a dose-dependent correlation between TEER reduction and anti-NS1 IgG level against all DENV serotypes from both DENV-naive vaccinees and DENV-infected serum pools ( Figure 5 ). An anti-DENV-2 NS1 IgG concentration of approximately 2000 relative ELISA units correlated with maximal protection against NS1-mediated endothelial hyperpermeability across DENV-1-4 for both postinfection and postvaccination sera, and the correlation curves almost completely overlapped for the TAK-003-vaccinated and DENV-infected sera for DENV-2 ( Figure 5B ). The highest NS1 IgG concentrations in DENV-naive vaccinees completely inhibited hyperpermeability mediated by DENV-1, -2, and -3 NS1 ( Figure 5A , 5C, and 5D), comparable to the immune response from DENV-infected individuals. However, the correlation curves were offset between vaccinated and infected serum in the cross-reactive response to DENV-1, -3, and -4 NS1. Additionally, DENV-4 NS1-mediated endothelial hyperpermeability was not completely inhibited by postvaccination serum from DENVnaive vaccinees. Therefore, cross-reactive antibodies may be qualitatively different after infection and vaccination.
Post-TAK-003 Vaccination Serum Prevents DENV-2 NS1-Induced
Degradation of Glycocalyx Components In Vitro
The endothelial glycocalyx is a major determinant of endothelial barrier function. We previously demonstrated that NS1 from DENV-1-4 triggers degradation of endothelial cell surface glycocalyx components in vitro [10, 11] . Using a subset of serum samples evaluated by TEER, we used confocal microscopy to visualize the effect of pre-and postvaccination sera from DENV-naive and preimmune subjects on NS1-induced disruption of sialic acid and heparan sulfate, 2 key components of the glycocalyx ( Figure  6 and Supplementary Figure 5 ). Positive control serum was used as a baseline for protection, and negative control serum represented maximum NS1-mediated disruption. Sialic acid and heparan sulfate expression levels in the presence of NS1 and control or TAK-003 recipient serum were imaged ( Figure 6A ) and quantitated ( Figure 6B and 6C) . Reflecting TEER results, we found that day 0 sera from DENV-naive patients had no substantial protective effect, while DENV-naive day 120 postvaccination sera completely blocked NS1-induced degradation of both sialic acid and heparan sulfate ( Figure 6A -6C and Supplementary Figure 5) . Similarly, day 0 samples from DENV-preimmune patients exhibited varying levels of protection, and preimmune day 120 postvaccination sera were completely protective ( Figure 6A -6C and Supplementary Figure 5 ). Taken together, these results suggest that the NS1-specific IgG response stimulated by TAK-003 can protect against NS1-induced hyperpermeability by preventing the degradation of key glycocalyx components.
DISCUSSION
Several lines of evidence highlight the importance of humoral and cell-mediated immune responses to nonstructural proteins, including NS1, in protection elicited by dengue vaccines [28] . The currently licensed live-attenuated dengue vaccine (Dengvaxia) does not include DENV NS1 [29] ; live-attenuated DENV-based vaccine candidates, including TAK-003, encode DENV NS1. While TAK-003 elicits cross-reactive NS1-specific CD8 + T-cell responses [30] , the humoral response to NS1 following vaccination had not been previously characterized. Here, we evaluated the magnitude and functionality of the NS1-specific IgG response elicited by TAK-003 and found that TAK-003 vaccination stimulates a robust anti-NS1 IgG response in DENV-naive vaccinees. Although levels of anti-NS1 IgG detected in DENV-naive vaccinees was significantly lower than levels in DENV-preimmune vaccinees after the first TAK-003 dose, NS1-specific IgG levels were comparable between the 2 groups after the second vaccine dose and persisted through 1 year postvaccination. Vaccination had a greater effect on NS1-specific IgG responses across all postvaccination time points in DENV-naive compared to DENV-preimmune recipients, likely due to high levels of anti-NS1 antibodies in many preimmune subjects prior to vaccination.
NS1 is the site of one of the attenuating mutations (an invariant glycine at position 53 to aspartate) in the DENV-2 backbone used for TAK-003 [31] . Using a panel of sera with high, medium, and low NS1-specific IgG concentrations, we observed no differences in ELISA concentrations to recombinant wildtype DENV-2 NS1 and TAK-003 NS1 encoding G53D (data not shown).
TAK-003 is a tetravalent formulation, with structural proteins from DENV-1-4, eliciting NAb responses against each serotype. The attenuated backbone is derived from DENV-2; thus, vaccination elicits IgG to DENV-2 NS1 in both DENV-naive and DENV-preimmune TAK-003 recipients, which cross-reacts with NS1 from DENV-1, -3, and -4. Cross-reactivity of anti-DENV-2 NS1 IgG in DENV-naive recipients was highest to DENV-1, followed by DENV-3 and DENV-4. Postvaccination sera from DENV-preimmune individuals were similarly cross-reactive across DENV-1-4. This trend may reflect inherent differences between cross-reactive antibodies in response to multiple infections in the preimmune group versus the first exposure to DENV NS1 postvaccination in naive subjects, especially because amino acid identity and homology between TDV-2 and DENV-1, -3, and -4 (Supplementary Table 3) does not exactly mirror the differences in anti-NS1 IgG cross-reactivity across the serotypes in naive vaccinees.
Recently, substantial progress has been made towards understanding the role of NS1 in dengue pathogenesis, and evidence suggests that NS1 is a mediator of vascular leak during DENV infection. NS1 has previously been explored as a vaccine candidate, and both NS1 recombinant protein and DNA vaccines are highly immunogenic and protective in mouse models [19, [32] [33] [34] . Naive mice that received adjuvanted recombinant NS1 or passive transfer of NS1-immune mouse sera or NS1-specific monoclonal antibodies (MAbs) were protected against DENV vascular leak disease, likely by preventing NS1-mediated pathogenesis and/or mediating lysis of DENV-infected cells [19, 35, 36] . Additionally, several immunodominant B cell NS1 epitopes conserved across DENV-1-4 have been identified in DENVinfected mice [37] , suggesting that an NS1 subunit or live DENV vaccine may protect against other DENV serotypes. We found that the TDV-2 NS1 IgG response in both DENV-naive and preimmune TAK-003 recipients is functional as it protects against DENV-2 NS1-induced endothelial hyperpermeability and EGL disruption, and this response correlates with the anti-TDV-2 NS1 antibody concentration. Blocking of DENV-2 NS1-mediated endothelial hyperpermeability by serum from DENV-naive vaccinees, DENV-preimmune vaccinees, or DENV-infected individuals was similar; however, the correlation trends varied among DENV serotypes. This suggests potential mechanistic differences in cross-reactivity driven by tetravalent vaccination versus natural infection. Comparison of the quality and quantity of the NS1-specific antibody repertoire after vaccination and natural infection could identify determinants of DENV-2-specific and cross-reactive NS1 immune responses elicited by vaccination, and this is the focus of future studies. Previous work has shown that anti-NS1 antibodies can activate complement (C′), most likely to lyse DENV-infected cells [38] . Though this may eliminate infected cells [39] , it could also contribute to pathogenesis if anti-NS1 antibodies recognize surface-bound soluble NS1 on noninfected cells, particularly endothelial cells. As such, further investigation into the repertoire of anti-NS1 antibodies elicited by TAK-003 vaccination in the context of complement activation is important, especially in light of recent work that identified an anti-NS1 MAb that triggers complement-mediated lysis of DENV-infected cells, presumably through antibody-dependent cell-mediated cytotoxicity [40] . Because NS1 plays multiple roles in pathogenesis, including activation of immune cells leading to inflammatory cytokine production [12] and complement interactions [39, 41] , it will be interesting to evaluate the effects of TAK-003 vaccination sera on other aspects of NS1 pathogenesis in vitro and in vivo. Overall, this is the first indication that vaccination stimulates an NS1-specific IgG response that is cross-reactive, functional, and may contribute to protection against severe dengue disease.
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